Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
Номер патента: EP4422753A1
Опубликовано: 04-09-2024
Автор(ы): Emmanuel DEAU, Frédéric MIEGE, Laurent Meijer, Pascal George
Принадлежит: Perha Pharmaceuticals
Опубликовано: 04-09-2024
Автор(ы): Emmanuel DEAU, Frédéric MIEGE, Laurent Meijer, Pascal George
Принадлежит: Perha Pharmaceuticals
Реферат: The present invention relates to a compound of formula (I) wherein R1 represents a (C4-C6)alkyl group, a (C3-C8)cycloalkyl group, a bridged (C6-C10)cycloalkyl group, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (C1-C3)alkanediyl group, and R' represents, a (C3-C8)heterocycloalkyl group, or a (C3-C8)heteroaryl group, or a R''-L- group wherein L is a (C1-C3)alkanediyl group, and R'' is an optionally substituted phenyl group; R2 is selected from the group consisting of a hydrogen atom and a (C1-C3)alkyl group; R5 represents a hydrogen atom, a (C1-C4)alkyl group or a (C3-C6)cycloalkyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits and neuroinflammation associated with Down syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; abnormal folate and methionine metabolism; osteoarthritis and tendinopathy; Duchenne muscular dystrophy; cancers and leukemias; neuroinflammation, anemia, infections caused by unicellular parasites, viral infections and for regulating body temperature.
Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
Номер патента: CA3236090A1. Автор: Laurent Meijer,Emmanuel DEAU,Pascal George,Frédéric MIEGE. Владелец: Perha Pharmaceuticals. Дата публикации: 2023-05-04.